63 results
Page 2 of 4
424B5
c3u7qytp36meyct yc
6 Aug 21
Prospectus supplement for primary offering
4:34pm
8-K
EX-1.1
2qwdzb4xpqnry
6 Aug 21
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-10.1
1hlyxbz1a7e6779pam
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTACĀ® Protein
7:30am
8-K
EX-1.1
xtduc3d217
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
424B5
rk3nev7nvmaj89l
16 Dec 20
Prospectus supplement for primary offering
4:01pm
424B5
aa0oul
14 Dec 20
Prospectus supplement for primary offering
4:48pm
S-3ASR
EX-4.5
qbk ez0zs1
14 Dec 20
Automatic shelf registration
4:02pm
S-3ASR
dvhm6mggfmwm 1aqnp3l
14 Dec 20
Automatic shelf registration
4:02pm
S-3ASR
EX-4.6
kkynlfn
14 Dec 20
Automatic shelf registration
4:02pm
8-K
2x4n4 vqfhk8ygjx
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
EX-99.1
vfzkkwytk9vtour
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTACĀ® Protein Degrader
7:06am